Breakout session C summary: current virus detection methods.

Area of Science:

• Biologics and Biopharmaceutical Manufacturing
• Virology and Molecular Biology
• Regulatory Science and Policy

Background:

• Adventitious viruses pose a significant risk to the safety and efficacy of biological products.
• Ensuring the purity of biologics requires robust methods for detecting and mitigating viral contamination.
• Regulatory bodies like the FDA play a crucial role in setting standards for viral safety.

Purpose of the Study:

• To bring together experts to discuss current challenges and advancements in adventitious virus detection.
• To explore effective strategies for mitigating viral contamination risks in biologic manufacturing processes.
• To foster collaboration between industry (PDA) and regulatory agencies (FDA) on viral safety.

Main Methods:

• Presentations and discussions on various viral detection technologies (e.g., PCR, sequencing, cell-based assays).
• Sharing of case studies and best practices for risk assessment and mitigation.
• Interactive sessions on regulatory expectations and future directions.

Main Results:

• Identified gaps and limitations in current viral detection methods.
• Highlighted the importance of a multi-pronged approach to viral safety, combining detection and mitigation.
• Emphasized the need for harmonized strategies and continuous improvement in the field.

Conclusions:

• Effective detection and mitigation of adventitious viruses are critical for ensuring the safety of biologics.
• Ongoing research and technological advancements are essential for staying ahead of potential viral threats.
• Collaboration between regulatory agencies and the biopharmaceutical industry is vital for maintaining high safety standards.